Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis | 59 | 2023 | 1904 | 5.510 |
Why?
|
Peru | 85 | 2024 | 881 | 3.710 |
Why?
|
Tuberculosis, Pulmonary | 30 | 2023 | 810 | 3.050 |
Why?
|
Tuberculosis, Multidrug-Resistant | 24 | 2023 | 910 | 2.210 |
Why?
|
Mycobacterium tuberculosis | 31 | 2023 | 1825 | 2.150 |
Why?
|
Antitubercular Agents | 29 | 2023 | 1319 | 1.980 |
Why?
|
Isoniazid | 8 | 2022 | 273 | 1.260 |
Why?
|
Latent Tuberculosis | 6 | 2023 | 225 | 0.870 |
Why?
|
Rifampin | 10 | 2023 | 315 | 0.800 |
Why?
|
Contact Tracing | 11 | 2023 | 272 | 0.800 |
Why?
|
Sputum | 11 | 2023 | 474 | 0.740 |
Why?
|
Nitroimidazoles | 3 | 2022 | 106 | 0.560 |
Why?
|
HIV Infections | 16 | 2024 | 16678 | 0.490 |
Why?
|
Family Characteristics | 10 | 2023 | 999 | 0.470 |
Why?
|
Health Personnel | 7 | 2022 | 3210 | 0.430 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 3915 | 0.420 |
Why?
|
Professional Competence | 1 | 2014 | 448 | 0.390 |
Why?
|
Prediabetic State | 3 | 2022 | 493 | 0.380 |
Why?
|
Adolescent | 53 | 2023 | 85649 | 0.370 |
Why?
|
Medication Adherence | 5 | 2023 | 2055 | 0.350 |
Why?
|
Mass Screening | 8 | 2023 | 5238 | 0.310 |
Why?
|
Mouth Mucosa | 2 | 2020 | 434 | 0.310 |
Why?
|
Antigens, CD1 | 2 | 2021 | 437 | 0.310 |
Why?
|
DNA, Bacterial | 4 | 2020 | 1465 | 0.300 |
Why?
|
Humans | 122 | 2024 | 742088 | 0.300 |
Why?
|
Health Services Accessibility | 5 | 2022 | 5133 | 0.290 |
Why?
|
Pyrazinamide | 2 | 2017 | 54 | 0.290 |
Why?
|
Child | 40 | 2023 | 77478 | 0.280 |
Why?
|
BCG Vaccine | 4 | 2018 | 367 | 0.280 |
Why?
|
Focus Groups | 4 | 2022 | 1320 | 0.270 |
Why?
|
Young Adult | 36 | 2023 | 56350 | 0.270 |
Why?
|
Child, Preschool | 26 | 2022 | 40955 | 0.270 |
Why?
|
Oxazoles | 3 | 2022 | 189 | 0.270 |
Why?
|
Infant | 24 | 2021 | 35070 | 0.240 |
Why?
|
Adult | 55 | 2023 | 213712 | 0.240 |
Why?
|
Bivalvia | 1 | 2023 | 53 | 0.240 |
Why?
|
Tuberculin Test | 6 | 2023 | 214 | 0.240 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2023 | 92 | 0.220 |
Why?
|
Prevalence | 11 | 2022 | 15194 | 0.220 |
Why?
|
Female | 68 | 2023 | 379592 | 0.220 |
Why?
|
Male | 63 | 2024 | 349538 | 0.220 |
Why?
|
Qualitative Research | 8 | 2023 | 2680 | 0.200 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2019 | 1872 | 0.200 |
Why?
|
Microbial Sensitivity Tests | 7 | 2023 | 1871 | 0.200 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2021 | 111 | 0.190 |
Why?
|
Transportation | 1 | 2022 | 211 | 0.190 |
Why?
|
Trehalose | 1 | 2021 | 88 | 0.190 |
Why?
|
Esters | 1 | 2021 | 210 | 0.190 |
Why?
|
Prisons | 1 | 2022 | 160 | 0.190 |
Why?
|
Prisoners | 1 | 2023 | 296 | 0.180 |
Why?
|
Infant, Newborn | 14 | 2020 | 25575 | 0.180 |
Why?
|
Sulfhydryl Compounds | 1 | 2021 | 296 | 0.180 |
Why?
|
HIV Long-Term Survivors | 1 | 2019 | 126 | 0.170 |
Why?
|
Sensitivity and Specificity | 7 | 2023 | 14720 | 0.170 |
Why?
|
Gastric Juice | 1 | 2018 | 64 | 0.170 |
Why?
|
Antigens, CD1d | 1 | 2019 | 220 | 0.170 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2018 | 563 | 0.170 |
Why?
|
Amides | 1 | 2021 | 458 | 0.160 |
Why?
|
Self Disclosure | 1 | 2019 | 251 | 0.160 |
Why?
|
Transients and Migrants | 1 | 2021 | 155 | 0.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 4751 | 0.160 |
Why?
|
Vitamin E Deficiency | 1 | 2018 | 32 | 0.160 |
Why?
|
Anti-HIV Agents | 2 | 2024 | 4250 | 0.160 |
Why?
|
Antibiotics, Antitubercular | 1 | 2018 | 104 | 0.160 |
Why?
|
Immunoglobulin M | 1 | 2023 | 1538 | 0.150 |
Why?
|
Geologic Sediments | 1 | 2018 | 76 | 0.150 |
Why?
|
Middle Aged | 36 | 2022 | 213127 | 0.150 |
Why?
|
Specimen Handling | 2 | 2022 | 692 | 0.150 |
Why?
|
Tuberculosis Vaccines | 1 | 2017 | 49 | 0.150 |
Why?
|
Suction | 1 | 2018 | 267 | 0.150 |
Why?
|
Directly Observed Therapy | 1 | 2018 | 137 | 0.150 |
Why?
|
National Health Programs | 2 | 2021 | 445 | 0.150 |
Why?
|
Communicable Disease Control | 2 | 2021 | 854 | 0.150 |
Why?
|
Amino Acid Motifs | 1 | 2019 | 936 | 0.150 |
Why?
|
Vitamin A Deficiency | 1 | 2017 | 101 | 0.150 |
Why?
|
Health Facilities | 1 | 2022 | 573 | 0.140 |
Why?
|
Ethambutol | 1 | 2016 | 60 | 0.140 |
Why?
|
Prospective Studies | 19 | 2022 | 53187 | 0.140 |
Why?
|
Actigraphy | 1 | 2020 | 488 | 0.140 |
Why?
|
Linkage Disequilibrium | 1 | 2021 | 1995 | 0.140 |
Why?
|
Case-Control Studies | 8 | 2022 | 21719 | 0.140 |
Why?
|
Viral Load | 3 | 2023 | 3292 | 0.140 |
Why?
|
Caregivers | 3 | 2023 | 2074 | 0.140 |
Why?
|
Comprehensive Health Care | 1 | 2017 | 127 | 0.140 |
Why?
|
Hypersensitivity, Immediate | 1 | 2019 | 334 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 804 | 0.130 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 602 | 0.130 |
Why?
|
Amidohydrolases | 1 | 2016 | 169 | 0.130 |
Why?
|
Health Literacy | 1 | 2020 | 414 | 0.130 |
Why?
|
Selection, Genetic | 1 | 2020 | 914 | 0.130 |
Why?
|
Parenting | 1 | 2021 | 676 | 0.130 |
Why?
|
Th17 Cells | 1 | 2021 | 765 | 0.120 |
Why?
|
Socioeconomic Factors | 4 | 2022 | 7770 | 0.120 |
Why?
|
Treatment Outcome | 17 | 2023 | 62966 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2021 | 1348 | 0.120 |
Why?
|
Entamoebiasis | 1 | 2013 | 14 | 0.120 |
Why?
|
Protozoan Infections | 1 | 2013 | 39 | 0.120 |
Why?
|
Quantitative Trait Loci | 1 | 2022 | 2015 | 0.120 |
Why?
|
Anticholesteremic Agents | 1 | 2021 | 979 | 0.120 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.120 |
Why?
|
Amebiasis | 1 | 2013 | 34 | 0.120 |
Why?
|
Genome, Bacterial | 1 | 2019 | 754 | 0.120 |
Why?
|
Blastocystis Infections | 1 | 2013 | 16 | 0.120 |
Why?
|
Income | 1 | 2023 | 1904 | 0.120 |
Why?
|
Social Class | 1 | 2023 | 1995 | 0.120 |
Why?
|
Bronchiectasis | 1 | 2015 | 128 | 0.120 |
Why?
|
Age Factors | 10 | 2021 | 18355 | 0.120 |
Why?
|
Social Stigma | 2 | 2023 | 698 | 0.120 |
Why?
|
Body Height | 1 | 2020 | 1574 | 0.120 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 24913 | 0.110 |
Why?
|
Phylogeny | 1 | 2021 | 2797 | 0.110 |
Why?
|
Vitamin E | 1 | 2018 | 869 | 0.110 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 5724 | 0.110 |
Why?
|
Feces | 1 | 2019 | 1394 | 0.110 |
Why?
|
Urban Population | 2 | 2020 | 2018 | 0.110 |
Why?
|
Molecular Epidemiology | 1 | 2015 | 468 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.110 |
Why?
|
Primary Prevention | 1 | 2020 | 1166 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 783 | 0.110 |
Why?
|
Drug Resistance, Bacterial | 2 | 2017 | 1032 | 0.110 |
Why?
|
Community Health Services | 1 | 2018 | 650 | 0.110 |
Why?
|
Disease Progression | 5 | 2021 | 13256 | 0.110 |
Why?
|
Parents | 2 | 2017 | 3387 | 0.110 |
Why?
|
Breast Feeding | 1 | 2021 | 1339 | 0.110 |
Why?
|
Risk Factors | 16 | 2023 | 72145 | 0.100 |
Why?
|
Mothers | 2 | 2021 | 2163 | 0.100 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1477 | 0.100 |
Why?
|
World Health Organization | 3 | 2023 | 1317 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3164 | 0.100 |
Why?
|
Cost of Illness | 1 | 2021 | 1852 | 0.100 |
Why?
|
Epidemics | 1 | 2017 | 521 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2020 | 1368 | 0.100 |
Why?
|
Nutritional Status | 2 | 2016 | 1606 | 0.100 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4554 | 0.100 |
Why?
|
Mutation, Missense | 1 | 2020 | 2556 | 0.090 |
Why?
|
Binding Sites | 1 | 2019 | 6115 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 9941 | 0.090 |
Why?
|
Medication Errors | 1 | 2017 | 797 | 0.090 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 3038 | 0.090 |
Why?
|
Clinical Protocols | 3 | 2022 | 1459 | 0.090 |
Why?
|
Logistic Models | 6 | 2023 | 13403 | 0.090 |
Why?
|
Weight Gain | 1 | 2020 | 2282 | 0.090 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1331 | 0.090 |
Why?
|
Sexual Behavior | 1 | 2019 | 2050 | 0.090 |
Why?
|
Incidence | 8 | 2020 | 20928 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2021 | 2068 | 0.090 |
Why?
|
Feasibility Studies | 4 | 2020 | 5062 | 0.090 |
Why?
|
Blood Glucose | 2 | 2021 | 6249 | 0.090 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2018 | 3920 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2026 | 0.080 |
Why?
|
Public Health | 1 | 2022 | 2594 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2014 | 814 | 0.080 |
Why?
|
Interviews as Topic | 1 | 2015 | 2536 | 0.080 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2023 | 323 | 0.080 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 2575 | 0.080 |
Why?
|
Cluster Analysis | 3 | 2021 | 2713 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2021 | 10163 | 0.080 |
Why?
|
Delayed Diagnosis | 2 | 2022 | 438 | 0.080 |
Why?
|
Health Behavior | 1 | 2019 | 2630 | 0.080 |
Why?
|
Aged | 16 | 2021 | 162944 | 0.080 |
Why?
|
Feeding Behavior | 2 | 2017 | 3187 | 0.080 |
Why?
|
Emotions | 1 | 2019 | 2657 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3843 | 0.070 |
Why?
|
Glucose Tolerance Test | 2 | 2020 | 1150 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3151 | 0.070 |
Why?
|
Genotype | 5 | 2019 | 12946 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2023 | 6483 | 0.070 |
Why?
|
Sex Factors | 4 | 2021 | 10392 | 0.070 |
Why?
|
Patient-Centered Care | 3 | 2022 | 1436 | 0.070 |
Why?
|
Social Support | 3 | 2022 | 2117 | 0.070 |
Why?
|
Quality Improvement | 1 | 2021 | 3738 | 0.070 |
Why?
|
Homosexuality, Male | 2 | 2024 | 1238 | 0.070 |
Why?
|
Vitamin D | 1 | 2019 | 3211 | 0.070 |
Why?
|
Multivariate Analysis | 5 | 2019 | 12242 | 0.070 |
Why?
|
Immunophenotyping | 2 | 2020 | 1866 | 0.060 |
Why?
|
Cohort Studies | 8 | 2021 | 40450 | 0.060 |
Why?
|
Psychometrics | 1 | 2014 | 2999 | 0.060 |
Why?
|
Comorbidity | 2 | 2017 | 10372 | 0.060 |
Why?
|
Area Under Curve | 2 | 2020 | 1653 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 15494 | 0.060 |
Why?
|
Sleep | 1 | 2020 | 4604 | 0.060 |
Why?
|
Treatment Failure | 2 | 2023 | 2615 | 0.060 |
Why?
|
Clofazimine | 1 | 2023 | 33 | 0.060 |
Why?
|
Pilot Projects | 3 | 2022 | 8297 | 0.060 |
Why?
|
Exercise | 1 | 2020 | 5611 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 17400 | 0.060 |
Why?
|
Tuberculin | 1 | 2022 | 65 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5304 | 0.050 |
Why?
|
Reverse Transcription | 1 | 2022 | 47 | 0.050 |
Why?
|
Smoking | 2 | 2021 | 8969 | 0.050 |
Why?
|
Odds Ratio | 3 | 2023 | 9846 | 0.050 |
Why?
|
Body Mass Index | 2 | 2017 | 12695 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2023 | 77098 | 0.050 |
Why?
|
Electrolytes | 1 | 2022 | 282 | 0.050 |
Why?
|
Pregnancy | 5 | 2023 | 29087 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2023 | 308 | 0.050 |
Why?
|
Pandemics | 4 | 2022 | 8328 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2021 | 57683 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 2524 | 0.050 |
Why?
|
Lung | 1 | 2020 | 9826 | 0.050 |
Why?
|
Factor Analysis, Statistical | 1 | 2023 | 975 | 0.050 |
Why?
|
Neck Pain | 1 | 2022 | 179 | 0.050 |
Why?
|
Microfibrils | 1 | 2020 | 17 | 0.050 |
Why?
|
Indians, South American | 1 | 2020 | 36 | 0.050 |
Why?
|
Weights and Measures | 1 | 2020 | 43 | 0.050 |
Why?
|
X-Rays | 1 | 2021 | 301 | 0.050 |
Why?
|
Primary Health Care | 1 | 2017 | 4551 | 0.050 |
Why?
|
Internet | 1 | 2012 | 3062 | 0.050 |
Why?
|
Mycolic Acids | 1 | 2020 | 54 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2022 | 39004 | 0.050 |
Why?
|
Asthma | 1 | 2019 | 5955 | 0.050 |
Why?
|
Regression Analysis | 2 | 2020 | 6452 | 0.040 |
Why?
|
Hospitals, Public | 1 | 2021 | 207 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 839 | 0.040 |
Why?
|
Heredity | 1 | 2020 | 154 | 0.040 |
Why?
|
Nasopharynx | 1 | 2022 | 379 | 0.040 |
Why?
|
Glycolipids | 1 | 2020 | 205 | 0.040 |
Why?
|
Administration, Oral | 2 | 2017 | 3913 | 0.040 |
Why?
|
Lipids | 2 | 2021 | 3302 | 0.040 |
Why?
|
Residence Characteristics | 2 | 2022 | 2049 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 256 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2020 | 229 | 0.040 |
Why?
|
Genes, MDR | 1 | 2018 | 37 | 0.040 |
Why?
|
Self Efficacy | 1 | 2022 | 610 | 0.040 |
Why?
|
Self-Help Groups | 1 | 2019 | 187 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 805 | 0.040 |
Why?
|
Automation, Laboratory | 1 | 2018 | 101 | 0.040 |
Why?
|
Health Services | 1 | 2023 | 758 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2019 | 13921 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2021 | 588 | 0.040 |
Why?
|
Gender Identity | 1 | 2023 | 681 | 0.040 |
Why?
|
Condoms | 1 | 2019 | 323 | 0.040 |
Why?
|
Hospitals, General | 1 | 2021 | 749 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2021 | 969 | 0.040 |
Why?
|
Skin Tests | 1 | 2019 | 612 | 0.040 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 494 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4801 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2020 | 19862 | 0.030 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 236 | 0.030 |
Why?
|
Conserved Sequence | 1 | 2019 | 1202 | 0.030 |
Why?
|
Triage | 1 | 2023 | 977 | 0.030 |
Why?
|
Spirometry | 1 | 2019 | 862 | 0.030 |
Why?
|
Lost to Follow-Up | 1 | 2016 | 105 | 0.030 |
Why?
|
Mutation | 2 | 2019 | 29717 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2012 | 4440 | 0.030 |
Why?
|
Biological Evolution | 1 | 2021 | 1074 | 0.030 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 880 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 369 | 0.030 |
Why?
|
Pregnant Women | 1 | 2020 | 566 | 0.030 |
Why?
|
Exercise Therapy | 1 | 2022 | 904 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2533 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7790 | 0.030 |
Why?
|
Risk Assessment | 3 | 2020 | 23320 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2019 | 971 | 0.030 |
Why?
|
Entamoeba | 1 | 2013 | 6 | 0.030 |
Why?
|
Endolimax | 1 | 2013 | 7 | 0.030 |
Why?
|
Blastocystis hominis | 1 | 2013 | 7 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 10943 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 2 | 2018 | 3014 | 0.030 |
Why?
|
Social Environment | 1 | 2019 | 1023 | 0.030 |
Why?
|
Carotenoids | 1 | 2017 | 624 | 0.030 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.030 |
Why?
|
Vitamin A | 1 | 2017 | 615 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2019 | 1179 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2018 | 414 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1284 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3133 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 627 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2303 | 0.030 |
Why?
|
Biological Assay | 1 | 2016 | 652 | 0.030 |
Why?
|
Bacteriological Techniques | 1 | 2014 | 276 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 512 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3587 | 0.030 |
Why?
|
Algorithms | 2 | 2023 | 13853 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3199 | 0.030 |
Why?
|
Diabetes Complications | 1 | 2019 | 1359 | 0.030 |
Why?
|
Interpersonal Relations | 1 | 2019 | 1423 | 0.030 |
Why?
|
Self Report | 1 | 2023 | 3548 | 0.030 |
Why?
|
Patient Compliance | 1 | 2022 | 2680 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2366 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2020 | 6365 | 0.030 |
Why?
|
Protein Conformation | 1 | 2019 | 4013 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2016 | 1661 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 7010 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2018 | 828 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2016 | 546 | 0.020 |
Why?
|
Computer Systems | 1 | 2012 | 483 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2019 | 1150 | 0.020 |
Why?
|
Health Expenditures | 1 | 2023 | 2346 | 0.020 |
Why?
|
Counseling | 1 | 2019 | 1521 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12220 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2183 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15056 | 0.020 |
Why?
|
Family | 1 | 2021 | 3144 | 0.020 |
Why?
|
Information Systems | 1 | 2012 | 410 | 0.020 |
Why?
|
Geographic Information Systems | 1 | 2012 | 281 | 0.020 |
Why?
|
Empathy | 1 | 2014 | 472 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1712 | 0.020 |
Why?
|
Genetic Loci | 1 | 2019 | 2572 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2593 | 0.020 |
Why?
|
Housing | 1 | 2014 | 663 | 0.020 |
Why?
|
Time Factors | 3 | 2017 | 40054 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 941 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4929 | 0.020 |
Why?
|
Models, Molecular | 1 | 2019 | 5454 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 676 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6534 | 0.020 |
Why?
|
Pain Measurement | 1 | 2018 | 3418 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2657 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 2997 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3527 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3339 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1265 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2557 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9387 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3585 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10248 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4664 | 0.020 |
Why?
|
Program Development | 1 | 2012 | 1314 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12344 | 0.020 |
Why?
|
Checklist | 1 | 2012 | 830 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9410 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9679 | 0.020 |
Why?
|
Language | 1 | 2014 | 1458 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2019 | 4231 | 0.020 |
Why?
|
Depression | 1 | 2023 | 7733 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2022 | 12071 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 3957 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4250 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5692 | 0.010 |
Why?
|
Genetic Variation | 1 | 2017 | 6540 | 0.010 |
Why?
|
Developing Countries | 1 | 2014 | 2789 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7901 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2014 | 3584 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 5979 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12705 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 12730 | 0.010 |
Why?
|
Chronic Disease | 1 | 2015 | 9144 | 0.010 |
Why?
|
Diet | 1 | 2017 | 7923 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5100 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15530 | 0.010 |
Why?
|
Mental Disorders | 1 | 2017 | 6587 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6934 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29010 | 0.010 |
Why?
|
United States | 1 | 2023 | 69693 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168561 | 0.010 |
Why?
|